TVRD Tvardi Therapeutics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Tvardi Therapeutics, Inc. (TVRD) SEC EDGAR filings in 2026, including the most recent 10-K annual report filed on March 31, 2026, a 10-Q quarterly report filed on May 8, 2026, an 8-K current report filed on July 30, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Tvardi Therapeutics, Inc. (TVRD) (SEC CIK 1346830), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
Go deeper on Tvardi Therapeutics, Inc.
Ask AI about TVRD filings. Chat with the 10-K, 10-Q, and 8-K for instant answers on financials, risks, and guidance.
Track institutional money. See which funds are building or cutting TVRD positions, quarter over quarter.
Catch cross-signals. Spot when insider buying, fund accumulation, and activist stakes line up on TVRD.
Quarterly Reports Archive10-Q
AI-powered analysis of Tvardi Therapeutics, Inc. (TVRD) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Tvardi Therapeutics, Inc. (TVRD) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2023 | FY2024 | FY2025 | |
|---|---|---|---|
| Profitability | |||
| Revenue | $21.0M | $7.1M | - |
| Operating Income | -$121.5M | -$58.4M | -$26.7M |
| Net Income | - | -$70.9M | -$18.2M |
| Op. Margin | -579.4% | -818.0% | - |
| Net Margin | - | -993.0% | - |
| Balance Sheet | |||
| Total Assets | $125.8M | $43.8M | $32.1M |
| Equity | - | -$4.6M | $20.9M |
| ROE | - | 1542.9% | -87.0% |
| Per Share | |||
| EPS | $-2.19 | $-15.53 | $-3.26 |
| Cash Flow | |||
| Operating CF | -$92.1M | -$60.9M | -$23.5M |
| CapEx | $2.4M | $1.0M | - |
Source: XBRL financial data from Tvardi Therapeutics, Inc. (TVRD) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Jul 30, 2026 | - | - | - |
8-K | Jul 17, 2026 | - | - | - |
8-K | Jul 7, 2026 | - | - | - |
8-K | Jun 11, 2026 | - | - | - |
8-K | May 8, 2026 | - | - | |
10-Q | May 8, 2026 | Mar 31, 2026 | - | |
10-K | Mar 31, 2026 | Dec 31, 2025 | - | |
8-K | Mar 31, 2026 | - | - | - |
8-K | Mar 6, 2026 | - | Analysis | - |
8-K | Jan 16, 2026 | - | - | |
8-K | Dec 18, 2025 | - | - | |
10-Q | Nov 13, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 14, 2025 | Jun 30, 2025 | - | |
10-Q | May 13, 2025 | Mar 31, 2025 | - | |
10-K | Mar 11, 2025 | Dec 31, 2024 | - | |
10-Q | Nov 14, 2024 | Sep 30, 2024 | - | |
SC 13D | Oct 30, 2024 | - | - | |
10-Q | Aug 14, 2024 | Jun 30, 2024 | - | |
10-Q | May 13, 2024 | Mar 31, 2024 | - | |
10-K | Mar 6, 2024 | Dec 31, 2023 | - | |
10-Q | Nov 13, 2023 | Sep 30, 2023 | - | |
10-Q | Aug 7, 2023 | Jun 30, 2023 | - | |
10-Q | May 15, 2023 | Mar 31, 2023 | - | |
10-K | Mar 6, 2023 | Dec 31, 2022 | - | |
SC 13G | Nov 18, 2022 | - | - |
13F Fund Holdings: Quarterly Trend
Latest: Q1 2026Aggregate TVRD share value held by 13F filers tracked by SignalX, by quarter.
- Northern Trust+1.2K (+3%)
- PNC Financial Services+225 (+77%)
- Citigroup+153 (+124%)
- State Street Corp18.3K (-16%)
- Renaissance Technologies LLC12.4K (-12%)
- Morgan Stanley11.6K (-14%)
- Goldman Sachs Group9.2K (-28%)
- Wells Fargo & Co3.8K (-62%)
- Vanguard Group Inc−424.8K
- Bank of America Corp−25.4K
- Citadel Advisors LLC−21.7K
- Two Sigma Investments−10.5K
- JPMorgan Chase & Co−2.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 56 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe.
Frequently Asked Questions
What are the latest TVRD SEC filings in 2026?
Tvardi Therapeutics, Inc. (TVRD) has filed a 10-K annual report on March 31, 2026, a 10-Q quarterly report on May 8, 2026, an 8-K current report on July 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did TVRD file its most recent 10-K annual report?
Tvardi Therapeutics, Inc. (TVRD) filed its most recent 10-K annual report on March 31, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view TVRD 10-Q quarterly reports?
Tvardi Therapeutics, Inc. (TVRD)'s most recent 10-Q quarterly report was filed on May 8, 2026. SignalX displays every TVRD 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has TVRD filed recently?
Tvardi Therapeutics, Inc. (TVRD)'s most recent 8-K was filed on July 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find TVRD insider trading activity (Form 4)?
SignalX aggregates every TVRD Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does TVRD file with the SEC?
Tvardi Therapeutics, Inc. (TVRD) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new TVRD filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Tvardi Therapeutics, Inc. (TVRD).
What is TVRD's SEC CIK number?
Tvardi Therapeutics, Inc. (TVRD)'s SEC CIK (Central Index Key) number is 1346830. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1346830 to look up all TVRD filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find TVRD return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Tvardi Therapeutics, Inc. (TVRD) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Tvardi Therapeutics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 80+ filings.